EGFR and non-small cell lung carcinoma: The literature on inherent resistance to 3G EGFR-TKIs primarily concerns osimertinib and is limited, given that this drug is approved as second line for T790M-positive, EGFR-mutant NSCLC patients, who have progressed on 1G/2G EGFR-TKIs.